Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 1/2015

01-01-2015 | Case Report

Alendronate-induced unmasking or deterioration of coeliac disease: a case series

Authors: B. G. A. Stuckey, R. Sallie

Published in: Osteoporosis International | Issue 1/2015

Login to get access

Excerpt

Osteoporosis is an increasing health problem in an ageing population. Bisphosphonates are one class of effective treatments. …
Literature
1.
Fleisch H (1993) Bisphosphonates: mechanisms of action and clinical use. In: Mundy GR, Martin TJ (eds) Physiology and pharmacology of bone, Handbook of experimental pharmacology. Springer-Verlag Berlin Heidelberg, New York, pp 377–418CrossRef
2.
Kemppainen T, Kroger H, Janatuinen E, Arnala I, Kosma VM, Pikkarainen P, Julkunen R, Jurvelin J, Alhava E, Uusitupa M (1999) Osteoporosis in adult patients with celiac disease. Bone 24:249–255PubMedCrossRef
3.
Pistorius LR, Sweidan WH, Purdie DW, Steel SA, Howey S, Bennett JR, Sutton DR (1995) Coeliac disease and bone mineral density in adult female patients. Gut 37:639–642PubMedCentralPubMedCrossRef
4.
Lindh E, Ljunghall S, Larsson K, Lavo B (1992) Screening for antibodies against gliadin in patients with osteoporosis. J Intern Med 231:403–406PubMedCrossRef
5.
Lebwohl B, Michaëlsson K, Green PHR, Ludvigsson JF (2014) Persistent mucosal damage and risk of fracture in celiac disease. J Clin Endocrinol Metab 99:609–616PubMedCrossRef
6.
Collin P, Kaukinen K, Maki M (1999) Clinical features of celiac disease today. Dig Dis 17:100–106PubMedCrossRef
7.
8.
9.
Giovanni C, Sanchez M, Straface E, Scazzocchio B, Silano M, Md V (2000) Induction of apoptosis in Caco-2 cells by wheat gliadin peptides. Toxicology 145:63–71CrossRef
10.
Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB (1995) Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443PubMedCrossRef
11.
Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D (2000) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517–525PubMedCrossRef
12.
Kelly R, Taggart H (1997) Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. Br Med J 315:1235CrossRef
13.
de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021PubMedCrossRef
14.
Parfitt JR, Driman DK (2007) Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 38:527–536PubMedCrossRef
15.
Peng YL, Hu HY, Luo JC, Hou MC, Lin HC, Lee FY (2014) Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study. Osteoporos Int 25:1617–1623PubMedCrossRef
16.
Mok JO, Jung CH, Kim CH, Ryu CB, Kim YJ, Kim SJ, Park HK, Suh KI, Yoo MH, Byun D-W (2013) Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females. Korean J Intern Med 28:694–700PubMedCentralPubMedCrossRef
17.
Twiss IM, Pas O, Ramp-Koopmanschap W, Den Hartigh J, Vermeij P (1999) The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res 14:784–791PubMedCrossRef
18.
Twiss IM, van den Berk AHM, de Kam ML, Bosch JJ, Cohen AF, Vermeij P, Burggraaf J (2006) A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans. J Clin Pharmacol 46:483–487PubMedCrossRef
19.
20.
Meek SE, Nix K (2007) Hypocalcemia after alendronate therapy in a patient with celiac disease. Endocr Pract 13:403–407PubMedCrossRef
21.
Metadata
Title
Alendronate-induced unmasking or deterioration of coeliac disease: a case series
Authors
B. G. A. Stuckey
R. Sallie
Publication date
01-01-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 1/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2942-8

Other articles of this Issue 1/2015

Osteoporosis International 1/2015 Go to the issue

Short Communication

Rapid access imaging for occult fractured neck of femur

Original Article

Bone density in healthy men after cessation of calcium supplements: 20-month follow-up of a randomized controlled trial

Original Article

Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy

Original Article

Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats

Case Report

Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy

Original Article

Serum levels of 25-hydroxyvitamin D and the occurrence of musculoskeletal diseases: a 3-year follow-up to the road study